RT Journal Article
SR Electronic
T1 Rethinking the residual approach: Leveraging machine learning to operationalize cognitive resilience in Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.19.24312256
DO 10.1101/2024.08.19.24312256
A1 Birkenbihl, Colin
A1 Cuppels, Madison
A1 Boyle, Rory T.
A1 Klinger, Hannah M.
A1 Langford, Oliver
A1 Coughlan, Gillian T.
A1 Properzi, Michael J.
A1 Chhatwal, Jasmeer
A1 Price, Julie T.
A1 Schultz, Aaron P.
A1 Rentz, Dorene M.
A1 Amariglio, Rebecca E.
A1 Johnson, Keith A.
A1 Gottesman, Rebecca F.
A1 Mukherjee, Shubhabrata
A1 Maruff, Paul
A1 Lim, Yen Ying
A1 Masters, Colin L.
A1 Beiser, Alexa
A1 Resnick, Susan M.
A1 Hughes, Timothy M.
A1 Burnham, Samantha
A1 Tunali, Ilke
A1 Landau, Susan
A1 Cohen, Ann D.
A1 Johnson, Sterling C.
A1 Betthauser, Tobey J.
A1 Seshadri, Sudha
A1 Lockhart, Samuel N.
A1 O’Bryant, Sid E.
A1 Vemuri, Prashanthi
A1 Sperling, Reisa A.
A1 Hohman, Timothy J.
A1 Donohue, Michael C.
A1 Buckley, Rachel F.
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312256.abstract
AB Cognitive resilience describes the phenomenon of individuals evading cognitive decline despite prominent Alzheimer’s disease neuropathology. Operationalization and measurement of this latent construct is non-trivial as it cannot be directly observed. The residual approach has been widely applied to estimate CR, where the degree of resilience is estimated through a linear model’s residuals. We demonstrate that this approach makes specific, uncontrollable assumptions and likely leads to biased and erroneous resilience estimates. We propose an alternative strategy which overcomes the standard approach’s limitations using machine learning principles. Our proposed approach makes fewer assumptions about the data and construct to be measured and achieves better estimation accuracy on simulated ground-truth data.Competing Interest StatementPaul Maruff is a full-time employee of Cogstate Ltd. Samuel N. Lockhart is a full time employee of Invicro LLC. SCJ has served in the past three years as a consultant to ALZPath and Enigma Biomedical.Funding StatementThis project is supported by R01AG079142. Coughlan is funded by a NIH Pathway to Independence award, K99AG083063, and an Alzheimer's Association Research Fellowship, AARF-23-1151259.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data were simulated and the scripts for simulation are available. https://github.com/Cojabi/inverse_learning ADAlzheimer’s diseaseCRcognitive resilience